| Literature DB >> 34168467 |
Yanhua Liang1, Shanglong Kou1,2, Xiaohe Li1, Zhiyi Ke1, Rongrong Zou1, Yanchao Pan1,3, Jing Yuan1.
Abstract
INTRODUCTION: The novel coronavirus (COVID-19) has become a global pandemic with sharp rises in the number of confirmed cases and rapid spread across the world. Here, we looked at the effects of geographic differences on clinical manifestations of SARS-CoV-2 infected patients.Entities:
Keywords: COVID-19 patients; clinical manifestations; geographic differences; inflammatory responses
Year: 2021 PMID: 34168467 PMCID: PMC8216746 DOI: 10.2147/IDR.S307238
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Baseline Characteristics of 114 COVID-19 Patients
| Overseas Group, N=50 | Local Chinese Group, N=64 | p value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| One-Way ANOVA | Tukey’s Post-Hoc Test | ||||||||||
| Foreign Travelers, N=10 | Overseas Chinese, N=40 | Foreigner vs Overseas Chinese | Foreigner vs Local | Overseas vs Local | |||||||
| Age (median, IQR) | 32.5 | (18.0–38.5) | 22 | (19.0–30.3) | 37.5 | (28.0–51.0) | 0.819 | 0.162 | |||
| Sex (Number, Percentage) | |||||||||||
| Male | 7 | 70.00% | 23 | 57.50% | 33 | 51.56% | 0.373 | 0.761 | 0.527 | 0.827 | |
| Female | 3 | 30.00% | 17 | 42.50% | 31 | 48.44% | |||||
| Definite contact history | 4 | 40.00% | 8 | 20.00% | 45 | 70.31% | 0.731 | ||||
| Comorbidities | 1 | 10.00% | 8 | 20.00% | 10 | 15.63% | 0.738 | 0.734 | 0.899 | 0.833 | |
| Initial signs and symptoms | |||||||||||
| Fever | 4 | 8.00% | 19 | 47.50% | 37 | 57.81% | 0.375 | 0.906 | 0.518 | 0.511 | |
| Cough | 3 | 6.00% | 20 | 50.00% | 10 | 15.63% | 0.296 | 0.159 | |||
| Phlegm | 0 | 0.00% | 10 | 25.00% | 6 | 9.38% | 0.101 | 0.699 | 0.064 | ||
| Admission Days | Laboratory parameters (mean+SD, 95% CI) | ||||||||||
| Day 1–3 | Lymphocyte (109/L) | 2.27±2.01 | (1.97–4.37) | 1.81±0.61 | (1.51–2.16) | 1.76±0.89 | (1.20–1.97) | 0.280 | 0.349 | 0.250 | 0.962 |
| WBC (109/L) | 5.50±1.71 | (3.79–7.00) | 5.10±1.54 | (4.30–5.12) | 5.30±1.78 | (4.07–5.57) | 0.752 | 0.783 | 0.933 | 0.837 | |
| Platelet (109/L) | 223.90±44.03 | (178.76–260.48) | 218.88±55.62 | (194.56–234.68) | 216.93±67.19 | (180.19–220.41) | 0.943 | 0.971 | 0.941 | 0.987 | |
| ALB (g/L) | 44.43±2.09 | (43.79–46.51) | 46.89±3.16 | (45.88–48.07) | 43.39±2.87 | (41.90–43.84) | 0.050 | 0.552 | |||
| CRP (mg/L) | 3.63±4.58 | (0.39–8.46) | 5.92±9.80 | (2.75–9.92) | 14.80±21.68 | (11.47–32.26) | 0.994 | 0.147 | |||
| IL-6 (pg/mL) | 3.84±2.42 | (2.12–6.15) | 4.50±4.15 | (3.32–6.31) | 8.36±7.81 | (6.03–12.31) | 0.953 | 0.111 | |||
| PCT(ng/mL) | 0.049±0.030 | (0.019–0.091) | 0.041±0.042 | (0.025–0.064) | 0.096±0.283 | (0.020–0.173) | 0.420 | 0.994 | 0.785 | 0.411 | |
| Day 4–8 | Lymphocyte (109/L) | 2.13±1.31 | (0.21–4.60) | 2.06±0.49 | (1.89–2.37) | 1.78±0.80 | (1.07–2.18) | 0.179 | 0.971 | 0.429 | 0.220 |
| WBC (109/L) | 5.21±0.95 | (3.79–6.30) | 5.40±2.17 | (3.98–5.16) | 5.93±2.68 | (4.56–8.73) | 0.501 | 0.974 | 0.679 | 0.566 | |
| Platelet (109/L) | 220.22±67.52 | (188.58–293.17) | 234.92±69.92 | (211.61–258.23) | 265.40±73.42 | (225.68–314.46) | 0.072 | 0.845 | 0.197 | 0.131 | |
| ALB (g/L) | 44.26±2.60 | (43.92–46.31) | 43.06±3.17 | (33.70–49.50) | 42.01±3.48 | (40.17–43.94) | 0.122 | 0.987 | 0.513 | 0.270 | |
| CRP (mg/L) | 5.39±10.36 | (0.98–9.71) | 6.19±12.39 | (1.47–10.90) | 12.06±17.38 | (6.84–17.28) | 0.207 | 0.991 | 0.493 | 0.244 | |
| IL-6 (pg/mL) | 2.76±2.25 | (0.68–4.85) | 5.32±8.94 | (1.45–9.18) | 7.91±11.32 | (2.76–13.07) | 0.418 | 0.809 | 0.436 | 0.641 | |
| PCT (ng/mL) | 0.024±0.006 | (0.019–0.028) | 0.106±0.38 | (0.001–0.258) | 0.052±0.104 | (0.022–0.082) | 0.508 | 0.606 | 0.935 | 0.575 | |
| Day 9–15 | Lymphocyte (109/L) | 2.00±0.43 | (1.68–2.72) | 1.96±0.60 | (1.77–2.29) | 1.97±0.89 | (1.40–2.07) | 0.994 | 0.993 | 0.994 | 0.999 |
| WBC (109/L) | 6.26±1.93 | (3.77–9.44) | 6.00±2.05 | (4.97–6.23) | 6.26±1.75 | (5.58–7.60) | 0.817 | 0.934 | 0.999 | 0.807 | |
| Platelet (109/L) | 240.88±62.55 | (219.00–275.27) | 245.90±48.91 | (229.42–271.88) | 289.43±75.35 | (275.02–325.82) | 0.981 | 0.142 | |||
| ALB (g/L) | 43.76±2.73 | (41.48–46.04) | 43.10±2.60 | (42.07–44.13) | 41.46±3.35 | (39.29–42.69) | 0.857 | 0.127 | 0.066 | ||
| CRP (mg/L) | 1.30±1.01 | (−13.99–39.08) | 3.27±4.92 | (1.19–2.73) | 5.25±6.58 | (2.91–10.17) | 0.122 | 0.685 | 0.181 | 0.346 | |
| IL-6 (pg/mL) | 3.30±2.61 | (0.89–5.71) | 2.74±1.54 | (1.98–3.51) | 4.46±2.65 | (3.61–6.01) | 0.854 | 0.466 | |||
| PCT (ng/mL) | 0.025±0.009 | (0.018–0.033) | 0.044±0.049 | (0.010–0.059) | 0.037±0.027 | (0.022–0.044) | 0.426 | 0.395 | 0.613 | 0.767 | |
| Day 16–22 | Lymphocyte (109/L) | 3.52±2.44 | (2.06–6.54) | 2.03±0.59 | (1.71–2.36) | 1.75±0.38 | (1.52–1.93) | 0.674 | |||
| WBC (109/L) | 6.74±2.28 | (3.91–9.57) | 6.25±1.38 | (5.48–7.02) | 6.11±1.30 | (5.42–6.88) | 0.703 | 0.796 | 0.679 | 0.962 | |
| Platelet (109/L) | 238.20±91.01 | (125.19–351.21) | 236.67±55.09 | (180.49–300.51) | 263.33±58.02 | (234.48–292.19) | 0.431 | 0.999 | 0.701 | 0.439 | |
| ALB (g/L) | 44.98±2.49 | (41.89–48.07) | 43.01±2.23 | (41.13–44.32) | 40.91±2.50 | (39.01–44.02) | 0.262 | 0.006 | |||
| CRP (mg/L) | 0.31±0.37 | (−0.15–0.77) | 4.38±4.43 | (0.37–3.55) | 5.15±7.38 | (1.35–8.94) | 0.193 | 0.174 | 0.271 | 0.894 | |
| IL-6 (pg/mL) | 1.50±0.30 | (1.48–1.54) | 2.19±0.77 | (−1.98–12.37) | 3.43±1.86 | (2.10–4.76) | 0.075 | 0.748 | 0.119 | 0.117 | |
| PCT (ng/mL) | 0.022±0.003 | (0.018–0.026) | 0.041±0.030 | (0.022–0.061) | 0.016±0.020 | (0.007–0.025) | 0.245 | 0.859 | |||
| Length of hospital stay (mean (day); (95% CI)) | 26.9±7.0 | (21.9–31.9) | 26.4±8.8 | (23.6–29.2) | 15.6±2.8 | (14.9–16.3) | 0.973 | ||||
Notes: Data are given as counts with percentage, mean ± SD with 95% CI, or median with range; for data not normally distributed, median with interquartile range (IQR) is used. Categorical variables are given as counts and percentages. Determined using one-way analysis of variance and p values in bold are considered to be significant.
Abbreviations: ALB, Albumin; CRP, C-reactive protein; IL-6, Interleukin-6; PCT, procalcitonin.
Figure 1Changes of laboratory parameters in the peri-hospitalization period. Comparisons on blood CRP (A) and IL-6 (B) indicated significantly higher inflammatory status in initial days of admission in local Chinese patients. Changes in ALB level (C) were identified with distinguishing levels among three groups. The local patients also presented with an obvious increase of the platelet count (D) and virus clearance rate (E), which were attenuated in overseas Chinese and foreign travelers. The independent two samples t-test is used between two groups and statistical tests are 2-tailed. A p value less than 0.05 is considered statistically significant. The asterisks indicate significant differences between the oversea Chinese and local Chinese patients (*p < 0.05, **p < 0.01, ***p < 0.001); the hash symbol indicates a significant difference between the foreign traveler and local Chinese groups (##p < 0.01, ###p < 0.001). Error bars: Mean ± SD.
Figure 2The Receiver Operator Characteristic (ROC) curves showing the performance of hematological parameters. The ROC curve analysis were performed on peripheral blood lymphocytes, platelets, CRP, IL-6 and ALB levels. The areas under the curve were calculated with the values of 0.57 (95% CI: 0.44–0.70, p = 0.294), 0.59 (95% CI: 0.46–0.72, p = 0.174), 0.33 (95% CI: 0.20–0.45, p = 0.007), 0.33 (95% CI: 0.21–0.45, p = 0.009), as well as 0.81 (95% CI: 0.72–0.90, p <0.001), respectively.